Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CTSD | P07339 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428702 | 0.86 | HDAC6 (0.40) | HDAC6DDB1CRBNBACE1TRPV1 | |
| SCHEMBL3404459 | 0.84 | FADS1 (0.43) | HDAC6DDB1CRBNPFKFB3 | |
| SCHEMBL4106465 | 0.84 | FADS1 (0.43) | HDAC6DDB1CRBNPFKFB3 | |
| SCHEMBL3401635 | 0.81 | HDAC6 (0.37) | HDAC6SLC6A4DDB1CRBNMAPT | |
| SCHEMBL26614673 | 0.81 | HDAC6 (0.47) | HDAC6SLC6A4BACE1CTSDTRPV1 | |
| SCHEMBL4099205 | 0.80 | TRPV1 (0.44) | HDAC6TRPV1MAPTCYP2C9 | |
| SCHEMBL4111676 | 0.79 | HDAC6 (0.39) | HDAC6TRPV1PFKFB3MAPT | |
| SCHEMBL4111354 | 0.79 | NAMPT (0.42) | HDAC6TRPV1CYP3A4CYP2C19 | |
| SCHEMBL4108756 | 0.78 | MAPT (0.43) | HDAC6TRPV1PFKFB3MAPTMAPK14 | |
| SCHEMBL4117005 | 0.78 | MAPT (0.39) | HDAC6BACE1TRPV1PFKFB3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2252372-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | HDAC6 884/4885SLC6A4 176/4885DDB1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.